New In-Vitro Study Finds Millipede88 with Corrugated Technology Outperformed Cyclic and Conventional Aspiration

Perfuze announced a peer-reviewed Clinical Neuroradiology study comparing three aspiration thrombectomy approaches for large-vessel-occlusion stroke in a benchtop model. The evaluation included super-bore aspiration with the Millipede88 catheter, cyclic aspiration through a 6F catheter, and conventional aspiration, supporting clinical visibility for next-generation stroke-treatment catheter technology.

Analysis

This is low-immediacy evidence rather than a valuation catalyst: benchtop thrombectomy performance does not establish clinical superiority, reimbursement support, physician adoption, or durable pricing power. The key gating variables are prospective human data, regulatory pathway timing, and whether the system can reduce procedure time or first-pass failure enough to overcome hospital switching costs. No public-equity read-through is sufficiently direct to warrant a trade today.

The more relevant competitive implication is that larger-bore aspiration, if validated clinically, could shift value from standalone aspiration-catheter suppliers toward companies controlling the full stroke-intervention workflow and hospital contracting channel. Medtronic (MDT), Stryker (SYK), Penumbra (PEN), and Johnson & Johnson (JNJ) face different exposures: PEN has the most concentrated neurovascular sensitivity, while MDT/SYK/JNJ can defend share through bundled device portfolios and sales infrastructure. A technically differentiated private entrant may therefore be more strategically relevant as an acquisition target than as a near-term revenue threat.

Over the next 6-18 months, watch for first-in-human outcomes, CE Mark/FDA milestones, and any evidence of lower rescue-device use; those would create a credible cost-offset argument for hospitals and raise competitive pressure on incumbent aspiration franchises. Conversely, failure to show better functional outcomes—not merely clot-removal mechanics—or any catheter-access and vessel-injury signal would materially weaken the thesis. Consensus is prone to overvalue favorable engineering studies in neurovascular devices, where clinical workflow and operator preference often determine commercialization more than bench performance.

Key Decisions for Investors

• No immediate position: treat this as a private-company competitive watch item, not a catalyst for MDT, SYK, PEN, or JNJ.
• Add PEN to a 6-18 month monitoring list; reassess a relative short versus diversified SYK or MDT only if Perfuze reports credible human data showing reduced procedure time, fewer passes, or lower rescue-device utilization alongside regulatory progress.
• For existing PEN exposure, monitor neurovascular segment growth and gross-margin guidance at each earnings release; a sustained deceleration versus stroke-procedure growth or explicit pricing pressure would validate an emerging competitive-risk thesis.
• Watch strategic M&A signals: a partnership, distribution agreement, or acquisition involving Perfuze would be more material for incumbent valuations than this publication. Lack of clinical validation or regulatory progress over the next 12 months falsifies the strategic-threat narrative.